6533b7d7fe1ef96bd1267a32

RESEARCH PRODUCT

The GERMELATOX DeCOG-trial : German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment

Ralf GutzmerClaus GarbeChristine BlomePatrick TerheydenT. KornekDirk SchadendorfKatharina C. KaehlerChristoffer GebhardtBarbara StadeFlorian SchenckAxel HauschildBerenice M. RudolphMatthias AugustinTobias WagnerJochen UtikalAndrea ForschnerOzan AnguenElisabeth LivingstoneCarmen LoquaiPeter Mohr

subject

OncologyCancer Researchmedicine.medical_specialtybusiness.industryMelanomamedicine.medical_treatmentMedizinmedicine.diseaseOncologyInterferonInternal medicineToxicitymedicinebusinessneoplasmsAdjuvantmedicine.drug

description

TPS9113^ Background: Although trials of adjuvant interferon alfa-2b (IFN alpha-2b) in high-risk melanoma patients suggest improvement in disease-free survival (DFS), a metaanalysis could only show ...

10.1200/jco.2014.32.15_suppl.tps9113